<p>Ikena Oncology（纳斯达克股票代码：IKNA - 获取免费报告）于周四公布了其财报。该公司报告本季度每股收益为（$0.06），超出分析师一致预期的（$0.14）$0.08，Zacks 报道。</p>
<p>获取 <strong>Ikena Oncology</strong> 的提醒：</p>
<h2>Ikena Oncology 股价上涨 4.4%</h2>
<p>周五午盘交易中，纳斯达克股票代码：IKNA 的股票上涨了 $0.06，达到 $1.43。该公司交易了 445,143 股，较其平均交易量 411,726 股有所增加。该公司的 50 日移动平均线为 $1.31，200 日移动平均线为 $1.32。Ikena Oncology 的一年最低价为 $0.97，一年最高价为 $1.94。该股票的市值为 6901 万美元，市盈率为-2.23，贝塔值为 0.50。</p>
<p>Ikena Oncology 的股票将于 7 月 28 日（星期一）进行反向拆分。1-12 的反向拆分于 7 月 25 日（星期五）宣布。股东所持股份的数量将在 7 月 25 日（星期五）市场收盘后进行调整。</p>
<h2>分析师评级变动</h2>
<p>另外，Wedbush 在周五的研究报告中将 Ikena Oncology 的目标股价从 $25.00 下调至 $23.00，并对该公司给予 “中性” 评级。</p>
<p><strong>查看我们关于 IKNA 的最新研究报告</strong></p>
<h2>对 Ikena Oncology 的对冲基金看法</h2>
<p>一家对冲基金最近增加了对 Ikena Oncology 股票的持股。高盛集团在第一季度将其在 Ikena Oncology, Inc.（纳斯达克股票代码：IKNA - 免费报告）的持股增加了 62.4%，根据其最近向证券交易委员会提交的 13F 表格。该基金在本季度购买了额外的 29,369 股后，持有 76,464 股该公司的股票。高盛集团在其最近向证券交易委员会提交的文件中显示，持有 Ikena Oncology 的股份占 0.16%，价值 98,000 美元。对冲基金和其他机构投资者持有该公司 75.00% 的股份。</p>
<h2>关于 Ikena Oncology</h2>
<p>（获取免费报告）</p>
<p>Ikena Oncology, Inc 是一家肿瘤学公司，专注于开发针对美国患者的差异化疗法，旨在针对癌症生长、扩散和治疗抵抗的节点。其主要项目是 IK-930，这是一种内部发现的、口服的、TEAD1 选择性的 Hippo 通路小分子抑制剂。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Ikena Oncology</li>
<li>消费者可选股票解析</li>
<li>加密怀疑论者仍可通过这些风险限制 ETF 获得丰厚回报</li>
<li>拥有债券的风险</li>
<li>3 只折扣钢铁股票，您今天可以进行定投</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>贝克休斯可能在无人机防御热潮中成为意外赢家吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 到 Ikena Oncology 吗？</h2>
<p>在您考虑 Ikena Oncology 之前，您需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前...而 Ikena Oncology 并不在名单上。</p>
<p>虽然 Ikena Oncology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IKNA

<p>Ikena Oncology（纳斯达克代码：IKNA）报告的季度每股收益为（$0.06），超出市场共识预期的（$0.14）$0.08。公告后，股价上涨 4.4%，至$1.43。高盛将其在该公司的持股增加了 62.4%，而 Wedbush 将其目标价从$25.00 下调至$23.00，维持 “中性” 评级。Ikena 的股票将于 7 月 28 日进行 1 比 12 的反向拆分。对冲基金持有该公司 75% 的股份，反映出强劲的机构投资兴趣</p>

<p>Ikena Oncology (NASDAQ:IKNA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08, Zacks reports.</p>
<div class="lb-trans"><p>Ikena Oncology（纳斯达克股票代码：IKNA - 获取免费报告）于周四公布了其财报。该公司报告本季度每股收益为（$0.06），超出分析师一致预期的（$0.14）$0.08，Zacks 报道。</p>
</div><p>Get <strong>Ikena Oncology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ikena Oncology</strong> 的提醒：</p>
</div><h2>Ikena Oncology Trading Up 4.4%</h2>
<div class="lb-trans"><h2>Ikena Oncology 股价上涨 4.4%</h2>
</div><p>Shares of NASDAQ:IKNA traded up $0.06 during midday trading on Friday, reaching $1.43. 445,143 shares of the company were exchanged, compared to its average volume of 411,726. The business's fifty day moving average is $1.31 and its two-hundred day moving average is $1.32. Ikena Oncology has a one year low of $0.97 and a one year high of $1.94. The stock has a market cap of $69.01 million, a PE ratio of -2.23 and a beta of 0.50.</p>
<div class="lb-trans"><p>周五午盘交易中，纳斯达克股票代码：IKNA 的股票上涨了 $0.06，达到 $1.43。该公司交易了 445,143 股，较其平均交易量 411,726 股有所增加。该公司的 50 日移动平均线为 $1.31，200 日移动平均线为 $1.32。Ikena Oncology 的一年最低价为 $0.97，一年最高价为 $1.94。该股票的市值为 6901 万美元，市盈率为-2.23，贝塔值为 0.50。</p>
</div><p>Ikena Oncology's stock is set to reverse split on Monday, July 28th. The 1-12 reverse split was announced on Friday, July 25th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, July 25th.</p>
<div class="lb-trans"><p>Ikena Oncology 的股票将于 7 月 28 日（星期一）进行反向拆分。1-12 的反向拆分于 7 月 25 日（星期五）宣布。股东所持股份的数量将在 7 月 25 日（星期五）市场收盘后进行调整。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Wedbush reduced their price objective on shares of Ikena Oncology from $25.00 to $23.00 and set a &#34;neutral&#34; rating for the company in a research note on Friday.</p>
<div class="lb-trans"><p>另外，Wedbush 在周五的研究报告中将 Ikena Oncology 的目标股价从 $25.00 下调至 $23.00，并对该公司给予 “中性” 评级。</p>
</div><p><strong>Check Out Our Latest Research Report on IKNA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IKNA 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Ikena Oncology</h2>
<div class="lb-trans"><h2>对 Ikena Oncology 的对冲基金看法</h2>
</div><p>A hedge fund recently raised its stake in Ikena Oncology stock. Goldman Sachs Group Inc. raised its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 62.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the quarter. Goldman Sachs Group Inc. owned 0.16% of Ikena Oncology worth $98,000 as of its most recent filing with the Securities &amp; Exchange Commission. Hedge funds and other institutional investors own 75.00% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对 Ikena Oncology 股票的持股。高盛集团在第一季度将其在 Ikena Oncology, Inc.（纳斯达克股票代码：IKNA - 免费报告）的持股增加了 62.4%，根据其最近向证券交易委员会提交的 13F 表格。该基金在本季度购买了额外的 29,369 股后，持有 76,464 股该公司的股票。高盛集团在其最近向证券交易委员会提交的文件中显示，持有 Ikena Oncology 的股份占 0.16%，价值 98,000 美元。对冲基金和其他机构投资者持有该公司 75.00% 的股份。</p>
</div><h2>About Ikena Oncology</h2>
<div class="lb-trans"><h2>关于 Ikena Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.</p>
<div class="lb-trans"><p>Ikena Oncology, Inc 是一家肿瘤学公司，专注于开发针对美国患者的差异化疗法，旨在针对癌症生长、扩散和治疗抵抗的节点。其主要项目是 IK-930，这是一种内部发现的、口服的、TEAD1 选择性的 Hippo 通路小分子抑制剂。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Ikena Oncology</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Crypto Skeptics Can Still Win Big With These Risk-Limiting ETFs</li>
<li>The Risks of Owning Bonds</li>
<li>3 Discounted Steel Stocks You Can DCA Into Today</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Could Baker Hughes Be an Unlikely Winner in Drone Defense Boom?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Ikena Oncology</li>
<li>消费者可选股票解析</li>
<li>加密怀疑论者仍可通过这些风险限制 ETF 获得丰厚回报</li>
<li>拥有债券的风险</li>
<li>3 只折扣钢铁股票，您今天可以进行定投</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>贝克休斯可能在无人机防御热潮中成为意外赢家吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IKNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ikena Oncology Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 到 Ikena Oncology 吗？</h2>
</div><p>Before you consider Ikena Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Ikena Oncology 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐购买，以便在更广泛的市场注意到之前...而 Ikena Oncology 并不在名单上。</p>
</div><p>While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ikena Oncology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ikena Oncology（NASDAQ:IKNA）公布了财报结果